ClinicalTrials.gg
CompletedNCT04908176Updated Dec 13, 2024

A Drug-drug Interaction Study of Avapritinib and Midazolam

A Phase 1 interventional study of Avapritinib and midazolam in Gastrointestinal Stromal Tumors, GIST and Non-resectable Advanced Solid Tumors, sponsored by Blueprint Medicines Corporation. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Gastrointestinal Stromal Tumors with a site in United States — 19 open to participants now, 29 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · United States.

Enrollment
103rd of 116
10 · median 55
Started
2022
with 4 others
Phase 1
32 of 139
3 open now
Registered
114th of 139
by date
Lead sponsor
3 of 139
Blueprint Medicines Corporation

Among the 139 studies in Gastrointestinal Stromal Tumors with a site in United States, this one is the 103rd largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2022, is one of 32 in phase 1, and was the 114th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

19 of the 139 studies in Gastrointestinal Stromal Tumors with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Gastrointestinal Stromal Tumors with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.

03

Conditions studied

  • Gastrointestinal Stromal Tumors
  • GIST
  • Non-resectable Advanced Solid Tumors
  • Recurrent or Unresectable Central Nervous System (CNS) Tumors

Keywords

  • Avapritinib
  • Midazolam
  • GIST
  • BLU-285
  • KIT
  • IDH-mutant astrocytoma
  • IDH-mutant oligodendroglioma
  • glioblastoma
  • H3K27-altered diffuse midline glioma
  • H3G34-mutant diffuse hemispheric glioma
  • midline glioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be ≥18 years of age at the time of signing the
  2. Confirmed diagnosis of

    • or unresectable KIT mutant GIST that has recurred or progressed after at least 4 lines of prior systemic SOC therapy or the Investigator has determined that treatment with SOC therapy is not appropriate for patients who failed at least 2 lines of prior SOC

    OR

    ---Non-resectable advance solid tumor with KIT mutation with progression following standard of care treatment.

    OR

    ---Confirmed diagnosis of recurrent or unresectable CNS tumors including :IDH-mutant astrocytoma, IDH-mutant oligodendroglioma, glioblastoma, H3K27-altered diffuse midline glioma, H3G34-mutant diffuse hemispheric glioma, midline glioma (with unknown H3K27 mutation status) that has failed prior radiation or systemic SOC therapy.

  3. Must be able to swallow an oral medication
  4. Must have (ECOG) performance status of 0 to 2
  5. Patient agrees to use consistent with local regulations
  6. Must provide signed informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Patients with GIST that harbors a known PDGFRA mutation
  2. Known to avapritinib, midazolam, or any of their
  3. Have received previous therapy with avapritinib
  4. Have any of the following laboratory abnormalities before the first dose of study drug:

    • (ALT) and aspartate aminotransferase (AST) >3 × (ULN) if no hepatic are present; >5 × ULN if hepatic metastases are present
    • Total >1.5 × ULN; >3 × ULN in the presence of Gilbert's Disease
    • Estimated ( formula) or measured creatinine clearance \<60 mL/min
    • count \<100 × 10\^9/liter (L)
    • (ANC) \<1.0 × 10\^9/L
    • \<9 grams per deciliter (g/dL). Transfusion and erythropoietin may be used to reach at least 9 g/dL but must have been administered at least 2 weeks before the first dose of the study drug.
  5. Require therapy with a concomitant medication that is a strong and moderate inhibitors or inducers
  6. Consumption of any nutrients known to modulate CYP3A4 enzymes activity (eg, grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange and derivative products, cruciferous vegetables [eg, broccoli, cauliflower, cabbage, brussel sprouts]) within 14 days before screening and during the study until the end of the Main Treatment Period
  7. Have received a prior anticancer drug less than 5 half-lives or 14 days (whichever is shorter) before screening
  8. Have had a major surgical procedure within 14 days of the first dose of study drug or have significant traumatic injury within 28 days before screening
  9. Have history of a cerebrovascular accident or within 1 year before screening
  10. Have known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding
  11. Have interval using Fridericia's formula (QTcF) >450 msec
  12. Have , uncontrolled, cardiovascular disease, including congestive heart failure Grades 2, 3, or 4 according to the classification, myocardial infarction, or unstable angina within the previous 6 months, or uncontrolled hypertension
  13. Have experienced any hemorrhage or bleeding event National Cancer Institute (NCI CTCAE) Version 5.0 Grade ≥3 within 4 weeks before screening. Exceptions are patients with primary CNS tumors who are eligible if the Grade ≥3 bleeding event was in the CNS and it occurred 2 weeks or more prior to the first dose of avapritinib.
  14. Patients who have a symptomatic nonhealing wound, ulcer, GI perforation, or bone fracture
  15. Have received organ or allogenic bone marrow or peripheral blood stem cell transplant
  16. Have known diagnosis of infection or active viral hepatitis; viral testing is not required
  17. History of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 14 grams of alcohol). Alcohol consumption will be prohibited 48 hours before screening and throughout the entire the Main Treatment Period
  18. Use of tobacco- or nicotine-containing products within 3 months of enrollment
  19. Is a female patient who is unwilling, if not or surgically sterile, to abstain from sexual intercourse or employ highly effective from the time of and for until at least 6 weeks after the last dose of study drug. Males who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of informed consent and for at least 6 weeks after the last dose of study drug.
  20. Is a female patient who is pregnant, as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy obtained within 7 days before the first dose of study drug. Patients with β-hCG values that are within the range for pregnancy but are not pregnant (false positives) may be enrolled with written consent of the Sponsor after pregnancy has been ruled out. Females of nonchildbearing potential (postmenopausal for more than 12 months, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) do not require a serum β-hCG test.
  21. Female who is breastfeeding
  22. Have a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the patient, alter the absorption, distribution, metabolism or excretion of the study drugs, or impair the assessment of study results.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Participants with metastatic, unresectable GIST, non-CNS solid tumors, or CNS tumors

    Participants will receive 5 mg of midazolam orally on Day 1 and Day 17. Participants will receive avapritinib 300 mg daily, orally on starting on Day 3. Participants with CNS tumors will receive avapritinib 300 mg daily orally, until Day 56.

    Drug: Avapritinib · Drug: midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. maximum plasma concentration (Cmax) of midazolam

    Time frame: Day 1 and Day 18

  2. time of maximum plasma concentration (tmax) of midazolam

    Time frame: Day 1 and Day 18

  3. area under the plasma concentration-time curve (AUC) of midazolam

    Time frame: Day 1 and Day 18

Secondary outcomes

  1. Number of adverse events (AEs), serious AEs (SAEs),

    Time frame: up to approximately 2 months

  2. Cmax at steady state (Cmax, ss) of avapritinib

    Time frame: Day 18

  3. Cmax at steady state (Cmax, ss) of metabolite

    Time frame: Day 18

  4. area under the plasma concentration-time curve at steady state (AUC,ss) of avapritinib

    Time frame: Day 18

  5. area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite

    Time frame: Day 18

07

Study locations

3 sites
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • University of Michigan
    Ann Arbor, Michigan 48103, United States
  • Thomas Jefferson University, Sidney Kimmel Cancer Center
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2024, 18 months.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jun 1, 2021
StartActual
Aug 24, 2022
Primary completionActual
Mar 1, 2024
CompletionActual
May 10, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04908176
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Aug 24, 2022
Primary completion
Mar 1, 2024
Completion
May 10, 2024
Last update
Dec 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avapritinib · Midazolam

Start the discussion